Search results
Showing 3226 to 3240 of 7685 results
This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.
This indicator covers the percentage of patients with diabetes, on the register, who have a record of retinal screening in the preceding 12 month. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM98.
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM96.
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
Angina and coronary heart disease: anti-platelet or anticoagulation (IND132)
This indicator covers the percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM88.
This indicator covers the percentage of patients with coronary heart disease (CHD) who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM87
Kidney conditions: CKD and renin–angiotensin system antagonists (IND130)
This indicator covers the percentage of patients on the chronic kidney disease (CKD) register who have hypertension and proteinuria and who are currently being treated with an angiotensin-receptor blocker or an angiotensin-converting enzyme inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM84
Hip fracture: formal hip fracture programme from admission (IND13)
This indicator covers the proportion of people with hip fracture, who receive a formal hip fracture programme from admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG20
This indicator ensures the contractor establishes and maintains a register of patients aged 18 years or over with chronic kidney disease (CKD) with classification of categories G3a to G5 (previously stage 3 to 5). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM83
Atrial fibrillation: current treatment with anticoagulation (IND128)
This indicator covers the percentage of patients who are currently treated with anticoagulation drug therapy in those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM82
This indicator covers the percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM81
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79